15 years of experience in phase 1
We are one of the leading EU providers of clinical research services. With over 15 years of experience in phase 1 clinical trials and a fully knowledgeable team, we carry out studies with the most stringent study protocols addressing your clinical study objectives. Biokinetica is your preferred partner in phase 1 studies – visit eng.biokinetica.com […]
Future drug prescribing
Will pharmacogenetic testing be a basis for future drug prescribing? Patients’ genetic variations affect how they metabolize medications and define whether a medicine is efficient for an individual. Tailoring medication and dosage for the patients based on their genetic information is the ultimate way to precision medicine.
Increase in the number of registered clinical trials
The number of registered clinical trials has increased significantly in recent years – from 2,119 registered trials in 2000 to 365,829 in 2021. Clinical trials grow more complex each year – it is important to partner with someone geared with skills and expertise throughout the development process. We have all the critical factors covered to […]
Genetic disorders
Although genetic disorders are individually rare, they account for approximately 80% of rare disorders – studying an individual’s genetic makeup can help identify signatures relating to disease states. Understanding genetics and –omics plays an increasingly important role in providing appropriate diagnosis and treatment for patients.
Targeted therapy for triple-negative breast cancer
In 2020, 2.3 million women were diagnosed with breast cancer and 685000 breast cancer deaths had occurred globally (World Health Organization). Thankfully, the cancer research does not stop – recently, researchers have developed a novel targeted therapy for triple-negative breast cancer that uses a revolutionary nano-carrier to deliver gambogic acid boosting the effectiveness of existing […]
Co-exclusive partnerships in biosimilar development
Besides applying our extensive clinical expertise, we are an avid global biosimilar market watcher. We recognized an increasing number of co-exclusive partnerships in biosimilar development to maximize market penetration. We are motivated in supporting our partners to succeed in the world of biosimilars.
Sequences from the exons of protein-coding genes
Analysis of DNA sequences from the exons of protein-coding genes constitutes a novel and cost-effective way to diagnose genetic diseases of all kinds. Many recent papers reveal how exome sequencing could contribute to novel prognostic categorization, finding new drug targets, or even clinical management changes.
Rare disease clinical trials
Nearly 8,000 rare diseases have been identified by researchers and affect an estimated 30 million people in the EU. It is crucial to ensure these patients are included in the drug decision-making and put at the centre of clinical trials. Biokinetica engages in rare disease clinical trials and is dedicated to helping find effective treatments […]
The patient is the subject of our work
There are humans behind every number. The positive impact of our work for patients and sustainable healthcare systems reinforces our aim and motivation. With the growing number of cost-effective biologics, we hope to keep supporting our partners in providing affordable medicines for all patients.
